Found 3 results
Filters: Author is C.J. Ma  [Clear All Filters]
M. Li, Ma, C. J., Liu, X. M., Zhao, D., Xu, Q. C., and Wang, Y. J., Molecular cloning of HSP70 in Mycoplasma ovipneumoniae and comparison with that of other mycoplasmas, vol. 10, pp. 834-848, 2011.
Amemiya K, Meyers JL, Deshazer D, Riggins RN, et al. (2007). Detection of the host immune response to Burkholderia mallei heat-shock proteins GroEL and DnaK in a glanders patient and infected mice. Diagn. Microbiol. Infect. Dis. 59: 137-147. doi:10.1016/j.diagmicrobio.2007.04.017 PMid:17908615 Barré A, de Daruvar A and Blanchard A (2004). MolliGen, a database dedicated to the comparative genomics of Mollicutes. Nucleic Acids Res. 32: D307-D310. doi:10.1093/nar/gkh114 PMid:14681420    PMCid:308848 Biberfeld G (1985). Infection Sequelae and Autoimmune Reactions in Mycoplasma pneumoniae Infection. Academic Press, Inc., Orlando, 293-311. Candiano G, Bruschi M, Musante L, Santucci L, et al. (2004). Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis 25: 1327-1333. doi:10.1002/elps.200305844 PMid:15174055 Chou SY, Chung TL, Chen RJ, Ro LH, et al. (1997). Molecular cloning and analysis of a HSP (heat shock protein)-like 42 kDa antigen gene of Mycoplasma hyopneumoniae. Biochem. Mol. Biol. Int. 41: 821-831. PMid:9111943 Craig EA (1985). The heat shock response. CRC Crit. Rev. Biochem. 18: 239-280. doi:10.3109/10409238509085135 Craig EA, Gambill BD and Nelson RJ (1993). Heat shock proteins: molecular chaperones of protein biogenesis. Microbiol. Rev. 57: 402-414. PMid:8336673    PMCid:372916 Dassanayake RP, Shanthalingam S, Herndon CN, Subramaniam R, et al. (2010). Mycoplasma ovipneumoniae can predispose bighorn sheep to fatal Mannheimia haemolytica pneumonia. Vet. Microbiol. 145: 354-359. doi:10.1016/j.vetmic.2010.04.011 PMid:20466492 Falah M and Gupta RS (1994). Cloning of the hsp70 (dnaK) genes from Rhizobium meliloti and Pseudomonas cepacia: phylogenetic analyses of mitochondrial origin based on a highly conserved protein sequence. J. Bacteriol. 176: 7748-7753. PMid:7528198    PMCid:197237 Falah M and Gupta RS (1997). Phylogenetic analysis of mycoplasmas based on Hsp70 sequences: cloning of the dnaK (hsp70) gene region of Mycoplasma capricolum. Int. J. Syst. Bacteriol. 47: 38-45. doi:10.1099/00207713-47-1-38 PMid:8995799 Floto RA, MacAry PA, Boname JM, Mien TS, et al. (2006). Dendritic cell stimulation by mycobacterial Hsp70 is mediated through CCR5. Science 314: 454-458. doi:10.1126/science.1133515 PMid:17053144 Foggie A, Jones GE and Buxton D (1976). The experimental infection of specific pathogen free lambs with Mycoplasma ovipneumoniae. Res. Vet. Sci. 21: 28-35. PMid:133436 Fraser CM, Gocayne JD, White O, Adams MD, et al. (1995). The minimal gene complement of Mycoplasma genitalium. Science 270: 397-403. doi:10.1126/science.270.5235.397 PMid:7569993 Himmelreich R, Hilbert H, Plagens H, Pirkl E, et al. (1996). Complete sequence analysis of the genome of the bacterium Mycoplasma pneumoniae. Nucleic Acids Res. 24: 4420-4449. doi:10.1093/nar/24.22.4420 PMid:8948633    PMCid:146264 Ionas G, Clarke JK and Marshall RB (1991). The isolation of multiple strains of Mycoplasma ovipneumoniae from individual pneumonic sheep lungs. Vet. Microbiol. 29: 349-360. doi:10.1016/0378-1135(91)90142-3 Jones GE, Foggie A, Mould DL and Livitt S (1976). The comparison and characterisation of glycolytic mycoplasmas isolated from the respiratory tract of sheep. J. Med. Microbiol. 9: 39-52. doi:10.1099/00222615-9-1-39 PMid:1263247 Kakeya H, Udono H, Maesaki S, Sasaki E, et al. (1999). Heat shock protein 70 (hsp70) as a major target of the antibody response in patients with pulmonary cryptococcosis. Clin. Exp. Immunol. 115: 485-490. doi:10.1046/j.1365-2249.1999.00821.x PMid:10193422    PMCid:1905239 Kiang JG and Tsokos GC (1998). Heat shock protein 70 kDa: molecular biology, biochemistry, and physiology. Pharmacol. Ther. 80: 183-201. doi:10.1016/S0163-7258(98)00028-X Kumar S, Tamura K and Nei M (2004). MEGA3: integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief. Bioinform. 5: 150-163. doi:10.1093/bib/5.2.150 PMid:15260895 Li X, Yang X, Li L, Liu H, et al. (2006). A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine. Vaccine 24: 3321-3331. doi:10.1016/j.vaccine.2006.01.012 PMid:16472546 Lin YC, Miles RJ, Nicholas RA, Kelly DP, et al. (2008). Isolation and immunological detection of Mycoplasma ovipneumoniae in sheep with atypical pneumonia, and lack of a role for Mycoplasma arginini. Res. Vet. Sci. 84: 367-373. doi:10.1016/j.rvsc.2007.06.004 PMid:17662318 Minion FC, Lefkowitz EJ, Madsen ML, Cleary BJ, et al. (2004). The genome sequence of Mycoplasma hyopneumoniae strain 232, the agent of swine mycoplasmosis. J. Bacteriol. 186: 7123-7133. doi:10.1128/JB.186.21.7123-7133.2004 PMid:15489423    PMCid:523201 Ramagli L (1999). 2-D Proteome Analysis. In: Methods in Molecular Biology (Link A, ed.). Humana Press, Totowa, 99-103. Rasoli M, Omar AR, Aini I, Jalilian B, et al. (2010). Fusion of HSP70 gene of Mycobacterium tuberculosis to hemagglutinin (H5) gene of avian influenza virus in DNA vaccine enhances its potency. Acta Virol. 54: 33-39. doi:10.4149/av_2010_01_33 PMid:20201612 Razin S, Yogev D and Naot Y (1998). Molecular biology and pathogenicity of mycoplasmas. Microbiol. Mol. Biol. Rev. 62: 1094-1156. PMid:9841667    PMCid:98941 Saitou N and Nei M (1987). The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4: 406-425. PMid:3447015 Scherm B, Gerlach GF and Runge M (2002). Analysis of heat shock protein 60 encoding genes of mycoplasmas and investigations concerning their role in immunity and infection. Vet. Microbiol. 89: 141-150. doi:10.1016/S0378-1135(02)00158-X Staint George TD and Carmichael LE (1975). Isolation of Mycoplasma ovipneumoniae from sheep with chronic pneumonia. Vet. Rec. 97: 205-206. doi:10.1136/vr.97.11.205 PMid:1162872 Suzue K and Young RA (1996). Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J. Immunol. 156: 873-879. PMid:8543845 Torigoe T, Tamura Y and Sato N (2009). Heat shock proteins and immunity: application of hyperthermia for immunomodulation. Int. J. Hyperther. 25: 610-616. doi:10.3109/02656730903315831 PMid:20021222
M. Y. Huang, Chen, M. J., Tsai, H. L., Kuo, C. H., Ma, C. J., Hou, M. F., Chuang, S. C., Lin, S. R., and Wang, J. Y., Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens, vol. 10, pp. 3002-3012, 2011.
Arnold D, Hohler T, Dittrich C, Lordick F, et al. (2008). Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Ann. Oncol. 19: 1442-1449. PMid:18441330 Bleiberg H (1996). Role of chemotherapy for advanced colorectal cancer: new opportunities. Semin. Oncol. 23: 42-50. Cunningham D, Humblet Y, Siena S, Khayat D, et al. (2004). Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351: 337-345. PMid:15269313 Department of Health, Executive Yuan (2007). Statistics on Leading Causes of Cancer Death. Bureau of National Health Insurance, Taiwan. Fakih M (2008). The role of targeted therapy in the treatment of advanced colorectal cancer. Curr. Treat. Options Oncol. 9: 357-374. PMid:19238551 Fang JY and Richardson BC (2005). The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 6: 322-327. Folprecht G, Lutz MP, Schoffski P, Seufferlein T, et al. (2006). Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann. Oncol. 17: 450-456. PMid:16303861 Giacchetti S, Perpoint B, Zidani R, Le Bail N, et al. (2000). Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 18: 136-147. PMid:10623704 Giovanella BC, Stehlin JS, Wall ME, Wani MC, et al. (1989). DNA topoisomerase I - targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046-1048. PMid:2555920 Hemming AW, Davis NL, Kluftinger A, Robinson B, et al. (1992). Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J. Surg. Oncol. 51: 147-152. PMid:1434639 Kallen KJ, Hofmann MA, Timm A, Godderz W, et al. (2000). Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma. Z. Gastroenterol. 38: 153-157. PMid:10721170 Lenz HJ, Van Cutsen E, Khambata-Ford S, Mayer RJ, et al. (2006). Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J. Clin. Oncol. 24: 4914-4921. PMid:17050875 Lievre A, Bachet JB, Boige V, Cayre A, et al. (2008). KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26: 374-379. PMid:18202412 Liu LF, Desai SD, Li TK, Mao Y, et al. (2000). Mechanism of action of camptothecin. Ann. N. Y. Acad. Sci. 922: 1-10. PMid:17132771 Loe DW, Deeley RG and Cole SP (1996). Biology of the multidrug resistance-associated protein, MRP. Eur. J. Cancer 32A: 945-957. Maindrault-Goebel F, de Gramont A, Louvet C, Andre T, et al. (2001). High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur. J. Cancer 37: 1000-1005. Martin-Martorell P, Rosello S, Rodriguez-Braun E, Chirivella I, et al. (2008). Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. Br. J. Cancer 99: 455-458. PMid:18665167    PMCid:2527794 Midgley RS, Yanagisawa Y and Kerr DJ (2009). Evolution of nonsurgical therapy for colorectal cancer. Nat. Clin. Pract. Gastroenterol. Hepatol. 6: 108-120. Min BS, Kim NK, Ahn JB, Roh JK et al. (2007). Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases. Onkologie 30: 637-643. PMid:18063876 Parkin DM, Bray F, Ferlay J and Pisani P (2005). Global cancer statistics, 2002. CA Cancer J. Clin. 55: 74-108. Pfeiffer P, Nielsen D, Yilmaz M, Iversen A, et al. (2007). Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. Acta Oncol. 46: 697-701. PMid:17562448 Recchia F, Candeloro G, Necozione S, Bratta M, et al. (2008). Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer. Am. J. Clin. Oncol. 31: 323-328. PMid:18845989 Reidy D and Saltz L (2007). Targeted strategies in the treatment of metastatic colon cancer. J. Natl. Compr. Canc. Netw. 5: 983-990. PMid:17977504 Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, et al. (2004). Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22: 1201-1208. PMid:14993230 Sambrook J, Jritsch E and Maniatis T (1989). Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, New York. Tabernero J, Van Cutsem E, Diaz-Rubio E, Cervantes A, et al. (2007). Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 25: 5225-5232. PMid:18024868 Teufel A, Steinmann S, Siebler J, Zanke C, et al. (2004). Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. BMC Cancer 4: 38. PMid:15265233    PMCid:497044 Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92: 205-216. PMid:10655437 van Ark-Otte J, Kedde MA, van der Vijgh WJ, Dingemans AM, et al. (1998). Determinants of CPT-11 and SN-38 activities in human lung cancer cells. Br. J. Cancer 77: 2171-2176. PMid:9649129    PMCid:2150393 Van Cutsem E, Kohne CH, Hitre E, Zaluski J, et al. (2009). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360: 1408-1417. PMid:19339720 Wang JY, Hsieh JS, Chen FM, Yeh CS, et al. (2003). High frequency of activated K-ras codon 15 mutant in colorectal carcinomas from Taiwanese patients. Int. J. Cancer 107: 387-393. PMid:14506738 Yen LC, Uen YH, Wu DC, Lu CY, et al. (2010). Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann. Surg. 251: 254-260. PMid:20010090